Atlas Venture Life Science Advisors, LLC Q2 2022 Filing
Filed August 3, 2022
Portfolio Value
$598.2B
Holdings
16
Report Date
Q2 2022
Filing Type
13F-HR
All Holdings (16 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | DAWNDay One Biopharmaceuticals, Inc. | 8,968,305 | $160.5B | 26.84% | |
| 2 | KYMRKymera Therapeutics, Inc. | 6,875,698 | $135.4B | 22.63% | |
| 3 | DYNDyne Therapeutics, Inc. | 8,934,902 | $61.4B | 10.26% | |
| 4 | REPLReplimune Group, Inc. | 3,209,627 | $56.1B | 9.38% | |
| 5 | GBIOGBXGeneration Bio, Co. | 8,278,876 | $54.3B | 9.08% | |
| 6 | AVTEAerovate Therapeutics, Inc. | 2,638,297 | $41.2B | 6.89% | |
| 7 | —Ikena Oncology, Inc. | 5,018,178 | $22.2B | 3.72% | |
| 8 | AKROAkero Therapeutics, Inc. | 2,232,251 | $21.1B | 3.53% | |
| 9 | VIGLVigil Neuroscience, Inc. | 5,836,874 | $15.1B | 2.52% | |
| 10 | —Gemini Therapeutics, Inc. | 5,254,365 | $8.9B | 1.48% | |
| 11 | XLOXilio Therapeutics, Inc. | 2,759,344 | $8.1B | 1.35% | |
| 12 | —Magenta Therapeutics, Inc. | 3,476,536 | $4.2B | 0.70% | |
| 13 | —AvroBio, Inc. | 4,520,863 | $4.2B | 0.70% | |
| 14 | —F-star Therapeutics, Inc. | 599,524 | $3.8B | 0.63% | |
| 15 | VRDNViridian Therapeutics, Inc. | 90,072 | $1.0B | 0.17% | |
| 16 | SPROSpero Therapeutics, Inc. | 1,031,160 | $764.0M | 0.13% |